Lilly Challenges US FDA Classification Of Obesity Drug Retatrutide, Citing Chevron Overturn
Chad Landmon, Hatch-Waxman & Biologics Chair, explains why the Lilly lawsuit exemplifies the type of cases expected in the post-Chevron world.
(subscription required)